Since the FDA greenlighted Novavax last month, clinical studies claiming less fevers and fatigue have driven people with long COVID and chronic fatigue syndrome to seek out the protein-based vaccine.

Last year's "triple-demic" marked the beginning of a confluence of respiratory infections that began to fill hospitals, which is why Biden has awarded companies $1 billion to develop COVID vaccines that provide longer protection.

Many health care professionals and scientists expressed outrage after the CDC released a draft of its proposals in June, concluding that N95 face masks are equivalent to looser, surgical face masks in certain settings.